Aequus Pharmaceuticals Inc. Closes on C$1.2 Million in Equity Financings, and In-Licenses Global Rights to Intellectual Property Enabling the Transdermal Delivery of Aripiprazole

VANCOUVER, British Columbia--(BUSINESS WIRE)--Aequus Pharmaceuticals Inc., a life sciences company specializing in transdermal reformulations of existing and approved drugs that address the difficult clinical problems of side-effects and patient compliance, announced today the closing of its first round of external financing. “With this amount raised, we are excited to further the development of our proprietary long-acting, transdermal application of aripiprazole, the world’s largest selling anti-psychotic in its branded oral form.. Over the coming months we expect to initiate human proof of concept studies, and begin filing new intellectual property on additional pipeline projects.” said Doug Janzen, President, Director and Co-Founder of Aequus Pharmaceuticals. “The amount raised was split equally between sophisticated investors from Canada and the United States, and we are pleased to welcome all of our new shareholders to this exciting new venture.”

Help employers find you! Check out all the jobs and post your resume.